Sonoma Pharmaceuticals (SNOA) Stock Statistics & Valuation Metrics

Sonoma Pharmaceuticals has a market cap or net worth of $5.77M. The enterprise value is $3.03M.

Sonoma Pharmaceuticals has 1,701,076 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sonoma Pharmaceuticals’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -37.57%.

The current PE Ratio of Sonoma Pharmaceuticals is ―. Sonoma Pharmaceuticals’s PEG ratio is 0.02.

In the last 12 months, Sonoma Pharmaceuticals had revenue of 14.29M and earned -3.46M in profits. Earnings per share was -2.79.

In the last 12 months, operating cash flow was -1.19M and capital expenditures -181.00K, giving a free cash flow of -1.37M billion.

Sonoma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Sonoma Pharmaceuticals upcoming earnings date is Feb 17, 2026, After Close (Confirmed).

Sonoma Pharmaceuticals as a current ratio of 3.09, with Debt / Equity ratio of 14.13%

In the past 12 months, Sonoma Pharmaceuticals has paid 550.00K in taxes.

Sonoma Pharmaceuticals EV to EBITDA ratio is 0.66, with an EV/FCF ratio of 14.00.

Sonoma Pharmaceuticals has $3.04M in cash and marketable securities with $535.00K in debt, giving a net cash position of $2.50M billion.

Gross margin is 37.68%, with operating margin of -25.97%, and net profit margin of -24.20%.

The average price target for Sonoma Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―